

MOL #73122

Title page

**Bharangin, a Diterpenoid Quinonemethide, Abolishes Constitutive and Inducible NF- κ B
Activation by Modifying p65 on Cysteine 38 residue and Inhibiting I κ B α Kinase
Activation, Leading to Suppression of NF- κ B-Regulated Gene expression and Sensitization
of Tumor Cells to Chemotherapeutic Agents**

Subash C. Gupta, Ramaswamy Kannapan, Ji Hye Kim, Ghazi M. Rahman, Sajin K. Francis,

Reshma Raveendran, Mangalam S. Nair, Joydip Das, and Bharat B. Aggarwal

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of

Texas MD Anderson Cancer Center, Houston, Texas, 77030 (S.C.G., R.K., J.H.K., B.B.A.)

Department of Pharmacological and Pharmaceutical Sciences, University of Houston, Houston,

Texas, 77204 (G.M.R., J.D.)

Organic Chemistry Section, National Institute for Interdisciplinary Science and Technology,

Trivandrum, Kerala, 695019, India (S.K.F., R.R., M.S.N.)

MOL #73122

Running title page

Running title: Bharangin inhibits NF- κ B–mediated cellular response.

Corresponding author:

Bharat B. Aggarwal

Department of Experimental Therapeutics, Unit 143,

The University of Texas MD Anderson Cancer Center,

1515 Holcombe Boulevard, Houston, TX 77030;

E-mail: aggarwal@mdanderson.org

Phone: 713-794-1817; Fax: 713-745-6339.

Number of text pages: 46

Number of tables: 1

Number of figures: 8

Number of references: 40

Number of words (Abstract): 249

Number of words (Introduction): 661

Number of words (Discussion): 1212

Abbreviations: AKT, AKT8 virus oncogene cellular homolog; ALLN, N-acetyl-leucyl-leucyl-norleucinal; AP-1, activator protein-1; Bax, Bcl-2–associated X protein; Bcl-2, B-cell lymphoma-2; Bcl-xL, B cell lymphoma extra large; BG, bharangin; cFLIP, caspase-8 (FLICE)-like inhibitory protein; c-Myc, cellular-myelocytomatosis; COX-2, cyclooxygenase-2; CSC, cigarette smoke condensate; CV, cell viability; DTT, dithiothreitol; EMSA, electrophoretic

MOL #73122

mobility shift assay; FBS, fetal bovine serum; FITC, fluorescein isothiocyanate; GSH, glutathione; GST, glutathione *S*-transferase; I κ B α , inhibitor of nuclear factor- κ B α ; IAP, inhibitor of apoptosis protein; ICAM-1, intercellular adhesion molecule-1; IKK, I κ B kinase; IMDM, Iscove's modified Dulbecco's medium; LPS, lipopolysaccharide; Mcl-1, myeloid cell leukemia-1; MEF, mouse embryonic fibroblast; MKK6, mitogen-activated protein kinase kinase 6; MMP-9, matrix metalloproteinase 9; MSK1, mitogen- and stress activated protein kinase 1; mTOR, mammalian target of rapamycin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF- κ B, nuclear factor-kappa B; NIK, NF- κ B-inducing kinase; OA, okadaic acid; Oct-1, octameric transcription factor 1; PAGE, polyacrylamide gel electrophoresis; PARP, poly(ADP-ribose) polymerase; PDK1, Phosphoinositide-dependent protein kinase-1; PI3K, phosphatidylinositol 3-kinase; PIS, preimmune serum; PMA, phorbol 12-myristate 13-acetate. PS, phosphatidylserine; ROS, reactive oxygen species; SEAP, secretory alkaline phosphatase; TAB1, TAK-1 binding protein-1; TAK, transforming growth factor- β -activated kinase; TNF, tumor necrosis factor; TNFR, TNF receptor; TRADD, TNFR-associated death domain; TRAF2, TNFR-associated factor 2; VEGF, vascular endothelial growth factor; XIAP, X-linked inhibitor of apoptosis protein.

MOL #73122

Abstract

Although inflammatory pathways have been linked with various chronic diseases including cancer, identification of an agent that can suppress these pathways has therapeutic potential. Herein we describe the identification of a novel compound bharangin, a diterpenoid quinonemethide that can suppress pro-inflammatory pathways specifically. We found that bharangin suppresses NF- κ B activation induced by pro-inflammatory cytokine, tumor promoter, cigarette smoke and endotoxin. Inhibition of NF- κ B activation was mediated through the suppression of phosphorylation and degradation of I κ B α ; inhibition of I κ B α kinase activation; and suppression of p65 nuclear translocation, and phosphorylation. The diterpenoid inhibited binding of p65 to DNA. A reducing agent reversed the inhibitory effect, and mutation of the Cys³⁸ of p65 to serine abrogated the effect of bharangin on p65-DNA binding. Molecular docking revealed strong interaction of the ligand with the p65 via two hydrogen bonds one with Lys³⁷ (2.204 Å) and another with Cys³⁸ (2.023 Å). The inhibitory effect of bharangin on NF- κ B activation was specific, in as much as binding of AP-1 and Oct-1 to DNA was not affected. Suppression of NF- κ B activation by this diterpenoid caused the down-regulation of the expression of proteins involved in tumor cell survival, proliferation, invasion, and angiogenesis leading to potentiation of apoptosis, suppression of proliferation and invasion of tumor cells. Further, the genetic deletion of p65 and mutation of p65Cys³⁸ residue to Ser abolished the affect of bharangin. Overall, our results demonstrate that bharangin specifically inhibits the NF- κ B activation pathway by modifying p65 and inhibiting I κ B α kinase activation and potentiates apoptosis in tumor cells.

MOL #73122

Introduction

Despite great strides in understanding cancer biology, oncologists have made very little progress in cancer prevention and treatment. On the contrary, World Health Organization projections indicate that cancer incidence will double over the next 20 years. Therefore, cancer research today is at a crossroads and requires thinking outside the box. Monotargeted drugs, once called smart drugs and magic bullets, have not had a great impact on cancer treatment. Recently, use of multi-targeted promiscuous drugs or a polypharmacological approach in cancer treatment has become increasingly accepted, as cancer is caused by dysregulation of multiple pathways. Most natural products used to treat cancer for centuries are known to have multiple targets and thus are preferred over mono-targeted drugs (Gupta et al. 2010a). Although medicinal plants have a long history of use in the treatment of cancer, what these plants are composed of and how their effects are mediated were unknown in ancient times. *Premna herbacea*, also known as *Clerodendrum indicum* (English: Tuber-flower, Turk's turban and skyrocket, Hindi: bharangi, Sanskrit: bhangī, Ayurvedic: nirgundi kul), is one such plant. Different parts of the plant have been used either alone or as an ingredient in preparations for the treatment of bronchitis, asthma, blood pressure, epilepsy, fever, inflammation, rheumatism, respiratory disorders, and helminthiasis and as an anti-nociceptive (Kirtikar and Basu, 1918; Narayanan et al., 2000; Nayar et al., 1976). Furthermore, *P. herbacea* extract has exhibited anti-cancer activity *in vitro* and in tumor-bearing mouse models (Boonyaratanakornkit and Chantapavan, 1993; Dhamija et al., 2008; Itharat et al., 1998; Kumar et al., 2008; Pai et al., 2008). Investigators have isolated a number of diterpenoids from the roots of this plant, one of which is bharangin (Sankaram et al., 1988; Sankaram and Rao, 1978; Sathish et al., 2009). Bharangin, a diterpenoid quinonemethide, chiefly present in *P. herbacea*, exhibited strong anti-microbial activity (Murthy et al., 2006) and reversed a drug-

MOL #73122

resistant phenotype of *Escherichia coli* cells carrying multidrug-resistant plasmids (Lakshmi et al., 1989). Also, the monoacetylated derivative of bharangin showed greater anti-microbial activity than that of bharangin (Murthy et al., 2006). Whether bharangin has anti-cancer activity has yet to be studied, however. Because extracts from the root nodules of *P. herbacea* exhibit anti-cancer and anti-inflammatory effects, we hypothesized that bharangin may be responsible for these effects.

Extensive research over the past three decades has revealed that most pro-inflammatory and carcinogenic effects of carcinogens are linked with activation of the nuclear factor (NF)- κ B pathway. NF- κ B is a pleiotropic transcription factor found in nearly all animal cell types. In resting cells, NF- κ B stays in an inactive state in the cytoplasm as a heterotrimer consisting of the subunits p50, p65, and the inhibitory subunit I κ B α . In response to a variety of inducers such as cytokines and growth factors, I κ B kinase (IKK) is rapidly activated which in turn phosphorylates I κ B α at Ser³² and Ser³⁶. Phosphorylated I κ B α then undergoes polyubiquitination and subsequent proteolytic degradation. After phosphorylation, p65 is released from the cytoplasm and translocated to the nucleus, where it binds to a specific DNA sequence and activates the transcription of more than 500 genes (Gupta et al. 2010a; Gupta et al. 2010b). Aberrant regulation of NF- κ B and the signaling pathways that control its activity is involved in inflammation, drug resistance, radioresistance, tumor survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells (Aggarwal, 2004). Therefore, agents that can down-modulate this pathway have potential in cancer therapy. We postulated that bharangin is one such agent that can modulate NF- κ B activation pathway.

In the present study, we investigated whether treatment with bharangin would modulate the survival and proliferation of tumor cells alone and in combination with currently used

MOL #73122

therapeutics. If so, we sought to investigate the mechanism by which this agent manifests these effects. We observed that this diterpenoid, 1) inhibited constitutive NF- κ B activation, 2) inhibited NF- κ B activation induced by carcinogens, tumor promoters, cigarette smoke and endotoxin, 3) inhibited binding of p65 with DNA, 4) inhibited IKK activation, 5) decreased the survival, and 6) enhanced the effects of currently used therapeutics in cancer cells.

MOL #73122

Material and Methods

Reagents: Bharangin (Figure 1A) was isolated from the acetone extract of the root nodules of *P. herbacea* using column chromatography and characterised by Infrared, ^1H NMR, ^{13}C NMR and Mass spectroscopy as well as melting point matching with that reported in literature (Sankaram et al., 1988). Human recombinant tumor necrosis factor (TNF)- α provided by Genentech was purified from bacterial cells to homogeneity with a specific activity of 5×10^7 U/mg. Cigarette smoke condensate (CSC) was provided by Dr. C. Gary Gairola (University of Kentucky). Penicillin, streptomycin, RPMI 1640, Iscove's modified Dulbecco's medium (IMDM), Dulbecco's modified Eagle's medium (DMEM), and fetal bovine serum (FBS) were obtained from Invitrogen. Phorbol myristate acetate (PMA), lipopolysaccharide (LPS), okadaic acid (OA), and an antibody against β -actin were obtained from Sigma. Antibodies against p50, cyclin D1, cyclooxygenase (COX)-2, matrix metalloproteinase (MMP)-9, poly (ADP-ribose) polymerase (PARP), inhibitor of apoptosis protein (IAP)-1, IAP-2, Bcl-2, Bcl-xL, Mcl-1, intercellular adhesion molecule (ICAM)-1, Bcl-2-associated X protein (Bax), cytochrome-c, c-Myc, AKT, caspases, mTOR, PI3K, MSK1, TAK1 and an annexin V staining kit were obtained from Santa Cruz Biotechnology. An anti-X-linked IAP (XIAP) was purchased from BD Biosciences. The PDK1 and phospho-specific anti-I κ B α (Ser^{32/36}), p65 (Ser²⁷⁶ and Ser⁵³⁶), PDK1 (Ser²⁴¹), PI3K [p85 (Tyr⁴⁵⁸) p55 (Tyr¹⁹⁹)], mTOR (Ser²⁴⁴⁸), MSK1 (Ser³⁷⁶) antibodies were purchased from Cell Signaling Technology. The antibody against survivin, p65, and vascular endothelial growth factor (VEGF) was purchased from R & D Systems, Abcam, and NeoMarkers, respectively. The I κ B α , IKK- α , IKK- β , phospho-AKT (Ser⁴⁷³), and cellular FLICE-inhibitory protein (c-FLIP) antibodies were obtained from Imgenex. The pcDNA3.1 and pcDNA expression vectors for mouse p65 and mouse p65C38S were kindly provided by Dr. T. D. Gilmore from Boston

MOL #73122

University (Boston, MA). The FuGENE 6 transfection reagent was obtained from Roche Applied Science (Indianapolis, IN).

Cell lines: The human cell lines U937 (leukemic monocyte lymphoma), HL-60 (promyelocytic leukemia), Jurkat (T-cell leukemia), A293 (embryonic kidney), H1299 (lung adenocarcinoma), U266, RPMI-8226, and MM.1S (multiple myeloma) were obtained from the American Type Culture Collection. The human cell line KBM-5 (chronic myeloid leukemia) was provided by Dr. Nicholas J. Donato (University of Michigan Comprehensive Cancer Center, Ann Arbor, MI) and K-562 (chronic myeloid leukemia) was obtained from Dr. Hesham Amin (The University of Texas MD Anderson Cancer Center). A mouse embryonic fibroblast (MEF) from p65^{-/-} C57BL/6J mice and its p65^{+/+} counterpart were provided by Dr. David Baltimore (California Institute of Technology). KBM-5 cells were cultured in IMDM with 15% FBS; K-562, HL-60, Jurkat, H1299, U937, RPMI-8226, MM.1S, and U266 cells were cultured in RPMI 1640 with 10% FBS; and A293 cells, p65^{+/+} MEFs, and p65^{-/-} MEFs were cultured in DMEM supplemented with 10% FBS. All culture media were supplemented with 100 U/mL penicillin and 100 µg/mL streptomycin.

Electrophoretic mobility shift assay (EMSA): To examine NF-κB activation in leukemia and myeloma cells, nuclear extracts were prepared, and an EMSA was performed using these extracts (Gupta et al. 2010c). The EMSAs for AP-1 and Oct-1 were performed as described for NF-κB using ³²P end-labeled double-stranded oligonucleotides.

Western blot analysis: Cytoplasmic, nuclear, and whole-cell extracts of untreated and treated

MOL #73122

cells were used in Western blot analysis (Gupta et al. 2011).

Invasion assay: To determine the effect of bharangin on TNF- α -induced invasion, the BD BioCoat tumor invasion system (BD Biosciences) was used employing a method as described previously (Gupta et al. 2010c).

Kinase assay: To examine the effect of bharangin on IKK and TGF- β -activated Kinase 1 (TAK1) activity, an immune complex kinase assay was performed using GST-I κ B α and His-MKK6 as substrate, respectively (Bharti et al., 2003).

Immunocytochemistry for NF- κ B p65 localization: To determine the effect of bharangin on nuclear translocation of p65, immunocytochemical analysis was performed (Pandey et al., 2007).

NF- κ B-dependent reporter gene expression: The effect of bharangin on induction of NF- κ B-dependent reporter gene transcription by TNF- α , TNF receptor (TNFR) 1, TNFR-associated death domain (TRADD), TNFR-associated factor 2 (TRAF2), NF- κ B-inducing kinase (NIK), TAK1/TAB1, IKK- β , and p65 was analyzed using a secretory alkaline phosphatase (SEAP) assay (Darnay et al., 1999).

Assessment of apoptosis using a live/dead assay: To assess the plasma membrane integrity and intracellular esterase activity, a live/dead assay was performed (Takada et al., 2004).

Analysis of apoptosis using a phosphatidylserine externalization assay: The loss of

MOL #73122

membrane asymmetry, which occurs when phosphatidylserine (PS) moves to the extracellular surface of the cell membrane, was measured using an annexin V staining kit according to the manufacturer's instructions.

Measurement of apoptosis and cell proliferation by mitochondrial dehydrogenase activity:

To determine the effect of bharangin on the proliferation of cancer cells and the cytotoxic potential of TNF- α and the chemotherapeutic agents, the mitochondrial dehydrogenase activity was measured using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) as a substrate (Bharti et al., 2003).

Transfection: A293 (5×10^5 cells/well) were plated in 6-well plates and transfected by FuGENE 6 transfection reagent with pcDNA3.1 or pcDNA expression vectors for mouse p65 or mouse p65C38S for 48 h. Thereafter, nuclear extracts from transfected cells were prepared, incubated with bharangin without or with DTT and then measured for DNA binding by EMSA. The p65^{-/-} cells were also transfected with p65C38S before treatment with bharangin and TNF- α to examine the sensitivity of these cells.

Molecular docking of bharangin into the NF- κ B p65: The energy minimized three-dimensional structure of bharangin was generated using CHEMBIODRAW 12 (CambridgeSoft) and SYBYL 8.0 (Tripos). For the receptor template, the crystal structure of NF- κ B p65 (PDB code: 2O61) was used. For docking of bharangin into NF- κ B p65, residue based docking mode was used in the SURFLEXDOCK module of SYBYL8.0. For protomol (three dimensional space into which the substrate docked) generation, the Cys³⁸ was used with pocket radius set to 3.0Å,

MOL #73122

bloat to 2 and threshold to 0.5. Ring flexibility, soft grid treatment, post and pre dock energy minimization were also applied in the docking procedure. The illustrations were made using UCSF Chimera (Pettersen et al., 2004).

Statistical analysis: Experiments were repeated a minimum of three times, with consistent results. The resulting data are presented as the mean \pm standard deviation (SD). Statistical analysis was carried out using a two-tailed unpaired Student *t*-test. *P* values less than 0.05 were considered statistically significant.

MOL #73122

Results

The aim of the present study was to determine whether bharangin has anti-cancer potential and, if so, via what mechanism. We used TNF- α in most of our studies because activation of the NF- κ B pathway by this cytokine is relatively well defined. We carried out most of the studies using KBM-5 chronic myeloid leukemia cells because 1) they express both types of TNF receptors and 2) the inflammatory pathway in these cells is better understood. However, we also used other cell types to determine the specificity of bharangin's effect.

Bharangin suppresses NF- κ B activation in tumor cells: We first investigated whether bharangin can modulate the NF- κ B activation pathway. Our results indicated that TNF- α induced NF- κ B activation, whereas bharangin alone did not (Figure 1B). Furthermore, pretreatment of cells with this quinonemethide suppressed TNF- α -induced NF- κ B activation in a dose- (Figure 1B) and time-dependent (Figure 1C) manner. Treatment with bharangin under these conditions had little effect on cell viability.

To confirm that the band visualized using EMSA was NF- κ B, we incubated nuclear extracts of TNF- α stimulated cells with antibodies against p50 and p65. Incubation with the antibodies shifted the band to a higher molecular mass (Figure 1D), suggesting that the TNF- α -activated NF- κ B complex consisted of both p50 and p65. Addition of excess unlabeled NF- κ B (cold oligonucleotide; 100-fold) caused a decrease in the band's intensity, whereas addition of a mutated oligonucleotide and preimmune serum (PIS) did not affect DNA binding.

Bharangin inhibits NF- κ B activation induced by carcinogens, tumor promoters, and other inflammatory agents: A variety of stimuli, including cigarette smoke condensate (CSC), OA,

MOL #73122

PMA, and endotoxin (LPS), can activate NF- κ B via different mechanisms. We found that all four of these agents activated NF- κ B in KBM-5 cells and that treatment with bharangin suppressed this activation in a dose-dependent manner (Figure 1E). These results suggest that the quinonemethide acts at a step in the NF- κ B activation pathway that is common to all five agents.

Bharangin-induced inhibition of NF- κ B activation is not cell type-specific: Because induction of NF- κ B activation is mediated by multiple pathways in different cell types, we investigated whether bharangin-mediated inhibition of TNF- α -induced NF- κ B activation is cell type-specific. We observed that the diterpenoid inhibited TNF- α -induced NF- κ B activation in different tumor cells (U937, HL-60, Jurkat, and K-562) in a dose-dependent manner (Figure 1F).

Bharangin inhibits constitutive NF- κ B activation in myeloma cells: Because most tumor cells are addicted to NF- κ B and those such as human multiple myeloma cells (U266) are known to express constitutive NF- κ B, we investigated whether treatment with bharangin inhibits NF- κ B activation in these cells. We found that bharangin inhibited constitutive NF- κ B activation in a dose-dependent manner (Figure 1G), indicating that bharangin can suppress not only inducible but also constitutive NF- κ B in tumor cells.

Bharangin does not inhibit AP-1 and Oct-1 activation in tumor cells: Whether bharangin inhibits activation of AP-1 and Oct-1 under the conditions it suppresses NF- κ B, was investigated. The results show that although TNF- α induced AP-1 in KBM-5 cells, pretreatment with bharangin had no effect on activity (Figure 1H, *left*).

MOL #73122

We next examined whether bharangin has ability to affect binding of AP-1 to DNA directly. We found that bharangin has no direct effect on binding of AP-1 to DNA (Figure 1H, *right*). We further tested the affect of bharangin on constitutive Oct-1 in KBM-5 cells. We found that bharangin has no affect on constitutive Oct-1(Figure 1I).

Bharangin inhibits I κ B α degradation: I κ B α is the inhibitory subunit of the NF- κ B complex that is proteolytically degraded before translocation of p65 from the cytoplasm to the nucleus. We therefore investigated whether inhibition of TNF- α -induced NF- κ B activation results from suppression of I κ B α degradation. The results showed that TNF- α induced NF- κ B activation in a time-dependent manner, whereas bharangin completely suppressed NF- κ B activation (Figure 2A). Also, TNF- α induced I κ B α degradation in KBM-5 cells as early as 10 min and I κ B α resynthesized at 60 min, whereas bharangin suppressed TNF- α -induced I κ B α degradation (Figure 2B).

Bharangin inhibits TNF- α -induced I κ B α phosphorylation: Before proteolytic degradation, I κ B α undergoes phosphorylation and ubiquitination. Therefore, we investigated whether inhibition of TNF- α -induced I κ B α degradation is caused by inhibition of I κ B α phosphorylation. Western blotting with an antibody that recognized the phosphorylated form of I κ B α (Ser³² and Ser³⁶) revealed that TNF- α induced phosphorylation of I κ B α , whereas bharangin completely suppressed this phosphorylation (Figure 2C).

Bharangin inhibits TNF- α -induced IKK activation: Because the presence of IKK is essential for TNF- α -induced I κ B α phosphorylation and bharangin inhibits I κ B α phosphorylation, we

MOL #73122

investigated the effect of bharangin on TNF- α -induced IKK activation. The results revealed that TNF- α activated IKK in KBM-5 cells in a time-dependent manner and that bharangin completely suppressed this activation (Figure 2D). Bharangin also inhibited constitutive IKK activation in U266 cells (Figure 2E).

We also sought to determine whether bharangin inhibits IKK activation by direct binding. We incubated an immunoprecipitated IKK complex with the diterpenoid at different concentrations and performed an IKK assay. We found that bharangin did not directly affect the activity of IKK (Figure 2F).

Bharangin inhibits TNF- α -induced TAK1 activation: Because TAK1 plays an essential role in the TNF- α -induced IKK and NF- κ B activation and bharangin failed to inhibit IKK activity directly, we sought to determine whether the inhibitory effect of bharangin on IKK is mediated through TAK1. Results of the TAK1 kinase assay revealed that bharangin suppressed TNF- α -induced TAK1 activation (Figure 2G). However, bharangin was unable to inhibit TNF- α -induced TAK1 activity directly (Figure 2H).

Bharangin inhibits TNF- α -induced AKT activation: IKK activation has been linked with activation of AKT (Ozes et al., 1999). Therefore, we investigated the affect of this diterpenoid on TNF- α -induced AKT activity. The results indicated that TNF- α induced AKT activation in a time-dependent manner and that bharangin inhibited this activation (Figure 2I).

Bharangin inhibits constitutive activation of PI3K, PDK1, mTOR and AKT: Next, we sought to determine whether bharangin has potential to inhibit constitutive AKT activation. If so,

MOL #73122

how does bharangin inhibits AKT activation was also investigated. We treated U266 cells with bharangin (5 μ M) for 0-6 hours and investigated the effect of this quinonemethide on AKT activation and on kinases upstream to AKT. We found that bharangin inhibited AKT activation in U266 cells. The inhibition in AKT activation was associated with decreased phosphorylation of PI3K, PDK1 and mTOR. However, the inhibitory affect of bharangin on mTOR phosphorylation was more prominent (Figure 2J).

Bharangin inhibits constitutive and TNF- α -induced nuclear translocation of p65:

In addition, we investigated whether inhibition of TNF- α -induced IKK activity and I κ B α degradation by bharangin is associated with inhibition of nuclear translocation of p65. An immunocytochemical analysis revealed that TNF- α induced translocation of p65 from the cytoplasm to the nucleus in KBM-5 cells. Pretreatment of the cells with bharangin suppressed this translocation, however (Figure 3A, *upper panel*). We also observed that the quinonemethide induced redistribution of p65 from the nucleus to the cytoplasm in U266 cells (Figure 3A, *lower panel*).

To confirm the results of immunocytochemical analysis, we performed Western blot analysis using nuclear extracts and an antibody against p65. The results indicated that TNF- α increased nuclear level of p65 in a time-dependent manner, whereas pretreatment of the cells with bharangin abolished this level (Figure 3B).

Bharangin inhibits phosphorylation of p65: TNF- α has been shown to induce phosphorylation of p65 at multiple sites, including Ser²⁷⁶ and Ser⁵³⁶, which is required for p65's transcriptional activity (Viatour et al., 2005). Therefore, we sought to determine the effect of bharangin on p65

MOL #73122

phosphorylation. As shown in Figure 3B, TNF- α induced phosphorylation of p65 at Ser²⁷⁶ and Ser⁵³⁶ in KBM-5 cells, whereas pretreatment of the cells with the diterpenoid completely suppressed this phosphorylation.

Bharangin inhibits phosphorylation of MSK-1: The phosphorylation of p65 at Ser²⁷⁶ is carried out by mitogen- and stress activated protein kinase 1 (MSK-1). Because bharangin inhibited p65 phosphorylation, we sought to determine the effect of this diterpenoid on MSK-1 activity. We found that the TNF- α induced MSK-1 phosphorylation in KBM-5 cells in a time dependent manner, while pretreatment with bharangin almost completely suppressed MSK-1 phosphorylation (Figure 3C).

Bharangin suppresses NF- κ B–dependent reporter gene expression: Using EMSA, we showed that bharangin inhibited NF- κ B activation. Because DNA binding alone does not always correlate with NF- κ B–dependent gene transcription, we sought to determine whether treatment with bharangin affects TNF- α –induced reporter gene transcription. To do so, we transiently transfected A293 cells with an NF- κ B–regulated SEAP reporter construct, treated them with bharangin, and then stimulated with TNF- α . We observed 8.8-fold greater induction of SEAP activity by TNF- α than by a vector control. The induction was completely suppressed by a dominant-negative I κ B α , indicating the specificity of the reporter gene assay. When we pretreated the cells with diterpenoid, TNF- α –induced, NF- κ B–dependent SEAP expression was inhibited in a dose-dependent manner (Figure 4A). These results indicated that bharangin inhibits NF- κ B–dependent reporter gene expression induced by TNF- α .

MOL #73122

Bharangin inhibits NF- κ B activation stimulated by TNFR1, TRADD, TRAF2, NIK,

TAK1/TAB1, IKK- β , and p65: Because TNF- α -induced NF- κ B activation is mediated through the sequential interaction of TNFR1 with TRADD, TRAF2, TAK1, and IKK- β , we sought to determine the site of action for bharangin in the TNF- α signaling pathway. A SEAP assay revealed that the plasmids TNFR1, TRADD, TRAF2, NIK, TAK1/TAB1, IKK- β , and p65 significantly induced reporter gene expression and that treatment with bharangin significantly suppressed this plasmid-induced expression (Figure 4B).

Bharangin interferes with the binding of p65 to DNA: We examined whether bharangin interfere with the binding of p65 to DNA. The results showed that the quinonemethide inhibited this binding, with maximum inhibition occurring at a concentration of 5 μ M (Figure 4C). These results suggested that bharangin inhibits binding of p65 to DNA.

Bharangin-induced inhibition of p65 binding to DNA is reversed by a reducing agent: A previous study showed that cysteine residues in p65 protein are crucial for DNA binding (Chen et al., 1998). Therefore, we investigated whether the inhibitory effect of bharangin on binding of NF- κ B to DNA can be reversed by treatment with the reducing agent dithiothreitol (DTT). We observed that DTT reversed the inhibitory effect of bharangin on DNA binding (Figure 4D).

Bharangin inhibits the binding of recombinant p65 to DNA, and DTT reverses this inhibition: To determine whether bharangin targets to the p65 subunit of NF- κ B, we transfected A293 cells with a p65-containing plasmid. EMSA results indicated that p65 bound to the DNA in

MOL #73122

these extracts and that bharangin suppressed this binding. In addition, DTT completely reversed bharangin-mediated inhibition of p65 binding to DNA (Figure 4E).

Mutation of Cys³⁸ in p65 to a serine abolishes the inhibitory effect of bharangin: Because Cys³⁸ in p65 is susceptible to modification, we investigated whether this residue is involved in the inhibitory effect of bharangin. We transfected A293 cells with a pcDNA3.1 or pcDNA expression vector containing p65^{+/+} or p65-C38S for 48 hours. We then incubated nuclear extracts of transfected cells with bharangin. EMSA results showed that bharangin inhibited the binding of p65^{+/+} but not mutated p65 to DNA (Figure 4F). These results indicated that Cys³⁸ in p65 is a target for bharangin.

Bharangin down-regulates the expression of inducible and constitutive NF- κ B-regulated cell survival proteins: Because NF- κ B is involved in the regulation of cell survival proteins and bharangin inhibits NF- κ B activation, we sought to determine whether this diterpenoid has potential to modulate expression of these proteins. We found that TNF- α induced expression of anti-apoptotic proteins such as Bcl-2, Bcl-xL, cIAP-1, and c-IAP-2, whereas pretreatment with bharangin down-regulated the expression of these proteins (Figure 5A, *left panel*). Bharangin also inhibited the constitutive expression of cell survival proteins in a concentration-dependent manner (Figure 5A, *right panel*).

Bharangin up-regulates the expression of pro-apoptotic proteins: We also examined whether bharangin modulates the expression of pro-apoptotic proteins. We observed that this diterpenoid

MOL #73122

up-regulated the expression of Bax and cytochrome-*c* in U266 cells in a dose-dependent manner (Figure 5B).

Bharangin suppresses the expression of proteins involved in tumor cell proliferation, invasion and angiogenesis: Furthermore, we investigated whether bharangin affects the expression of proteins involved in tumor cell proliferation, such as cyclin D1, c-Myc, and COX-2. The results indicated that the diterpenoid inhibited both inducible (Figure 5C, *left panel*) and constitutive (Figure 5C, *right panel*) expression of these proliferative proteins. In addition, we found that the quinonemethide inhibited both inducible and constitutive expression of ICAM-1, MMP-9, and VEGF (Figure 5D).

Bharangin suppresses the proliferation of tumor cells: Next, we examined the effect of bharangin on the proliferation of tumor cells. We found that this diterpenoid suppressed the proliferation of myeloid leukemia (KBM-5, HL-60, U937, and K-562), T-cell lymphoma (Jurkat), and myeloma (U266, MM.1S, and RPMI-8226) cells in a dose- and time-dependent manner. Furthermore, at concentrations as low as 1 μ M, bharangin inhibited the proliferation of cancer cells after 3 days of treatment (Figure 6A).

Bharangin potentiates apoptosis induced by TNF- α and chemotherapeutic agents in tumor cells: TNF- α is one of the most effective apoptosis-inducing cytokines (Aggarwal, 2003). We examined whether bharangin potentiates TNF- α -induced apoptosis. As determined by examining intracellular esterase activity, we found that bharangin enhanced TNF- α -induced apoptosis in KBM-5 and U266 cells in a dose-dependent manner. Specifically, TNF- α -induced

MOL #73122

apoptosis was increased from 8% to 52% in KBM-5 cells and from 7% to 40% in U266 cells (Figure 6B).

To confirm the results of intracellular esterase activity, we assessed the mitochondrial dehydrogenase activity. The results indicated that bharangin potentiated TNF- α -induced apoptosis not only in KBM-5 and U266 cells but also in other cancer cells (Table 1).

We next examined whether treatment with bharangin can enhance apoptosis induced by chemotherapeutic agents. We found that this diterpenoid potentiated the apoptotic effects of both 5-fluorouracil and thalidomide in various tumor cells (Table 1).

One of the very early events of apoptosis is externalization of the membrane PS on the cell surface. Because of annexin V's affinity for PS, staining for annexin V can be used to detect early apoptotic cells. Therefore, we examined the effect of treatment with bharangin on PS externalization induced by TNF- α . We found that the number of annexin V-positive cells increased significantly when we pretreated the cells with bharangin before TNF- α (Figure 6C).

Bharangin in combination with TNF- α induces PARP cleavage and caspase activation: One of the hallmarks of apoptosis is the cleavage of PARP from the native 116 kDa to 89 kDa protein that is mediated through activation of caspases. We therefore investigated whether treatment with quinonemethide enhances TNF- α -induced activation of caspase-3, caspase-8, and caspase-9 and cleavage of PARP. We found that TNF- α alone had little effect on PARP cleavage and caspase activation but that pretreatment of the cells with bharangin sensitized them to PARP cleavage (Figure 6D) and caspase activation (Figure 6E).

Bharangin suppresses TNF- α -induced tumor-cell invasion: We also investigated whether

MOL #73122

treatment with bharangin can modulate TNF- α -induced tumor-cell invasion. We found that TNF- α increased the tumor cell invasion almost 3.6-fold. Whereas treatment with bharangin alone had no effect, pretreatment significantly reduced TNF- α -induced tumor cell invasion (Figure 6F).

Deletion of p65 abolishes the effect of bharangin on TNF- α -induced apoptosis: p65 is known to be the active subunit of NF- κ B, which regulates anti-apoptotic gene products. Thus far, all of the results have indicated that bharangin interferes with the NF- κ B pathway. We investigated whether deletion of p65 affects the potentiation of TNF- α -induced apoptosis by bharangin. We found that bharangin potentiated TNF- α -induced apoptosis from 7% to 48% in p65^{+/+} MEFs. In p65^{-/-} MEFs lacking functional NF- κ B, TNF- α induced apoptosis by 43%. The diterpenoid neither had an effect alone nor significantly potentiated the apoptosis induced by TNF- α in p65^{-/-} MEFs (Figure 7A). Taken together, these results indicated that deletion of p65 abolished the potentiation of TNF- α -induced apoptosis by bharangin.

Suppression of TNF- α -induced expression of anti-apoptotic proteins by bharangin

requires functional p65: We determined whether the presence of functional p65 is essential for the inhibitory effects of bharangin on TNF- α -induced expression of anti-apoptotic gene products, we used both p65^{+/+} and p65^{-/-} MEFs. The results showed that TNF- α -induced anti-apoptotic proteins and that bharangin inhibited this induction in p65^{+/+} MEFs. In p65^{-/-} MEFs, however, TNF- α failed to induce expression of anti-apoptotic proteins (Figure 7B). These results suggested that the presence of functional p65 is essential for the induction and inhibition of anti-apoptotic proteins.

MOL #73122

Introduction of p65 C38S in MEF-p65^{-/-} cells decreases sensitivity to bharangin: Because p65 (C38S) mutant exhibited resistance to NF- κ B inhibition by bharangin, we sought to determine the sensitivity of these mutants to apoptosis potentiation by bharangin. For this, we transfected p65^{-/-} cells with p65 (C38S) plasmid, treated first with bharangin and then stimulated with TNF- α . We found that neither TNF- α induced apoptosis nor did bharangin potentiate the apoptosis (Figure 7C, *left panel*). Finally, we examined the ability of bharangin to modulate anti-apoptotic proteins in these cells. Although TNF- α induced anti-apoptotic proteins in a time dependent manner, pretreatment with bharangin had an insignificant affect (Figure 7C, *right panel*). Taken together, these results suggest the importance of p65 C38 in the determining sensitivity against bharangin.

MOL #73122

Discussion

Up to 70% of anti-cancer drugs are derived from natural products. Traditional medicine using natural products has served mankind for thousands of years, but neither their active components nor their mechanisms of action are well understood. In the present study, we identified bharangin, a compound derived from a plant routinely used in traditional medicine and delineated the cell signaling pathway by which its anti-cancer effects are mediated. Our results demonstrated that this diterpenoid exhibits anti-cancer, anti-inflammatory, and immunomodulatory effects via modulation of pro-inflammatory pathways.

We found that bharangin inhibits NF- κ B activation induced by pro-inflammatory cytokine, tumor promoter, cigarette smoke and endotoxin. The inhibition of NF- κ B activation by bharangin was specific as it failed to inhibit AP-1 and Oct-1 activation. How bharangin inhibits TNF- α -induced NF- κ B activation was investigated. The IKK complex is an important site of integration of signals that regulate the NF- κ B pathway. We found that this quinonemethide inhibits IKK activity, leading to inhibition of phosphorylation and degradation of I κ B α and nuclear translocation of p65. Our results indicated that this diterpenoid is not a direct inhibitor of IKK activation, suggesting that kinases upstream of IKK are involved. Several kinases, including AKT (Ozes et al., 1999), and TAK1 (Sakurai et al., 1999) reportedly function upstream of IKK. Our results indicated that bharangin may inhibit IKK activation via inhibition of TAK1 and AKT activation. The ability of bharangin to inhibit PI3K, PDK1 and mTOR activation indicates that bharangin may mediate its inhibitory affect on AKT activation through PI3K/PDK1/mTOR pathway. However, how this diterpenoid inhibits TAK1 remains to be elucidated.

We also found that bharangin inhibits NF- κ B activation by modifying p65 subunit of NF- κ B. These results are consistent with our findings that bharangin suppressed p65-induced NF- κ B

MOL #73122

reporter activity. Previous studies have shown that a Cys³⁸ residue in p65 is crucial for DNA binding (Chen et al., 1998). This residue contacts a phosphate in the DNA backbone, is responsible for redox regulation of NF-κB (Ghosh et al., 1995; Muller et al., 1995) and has to be in reduced state in order to bind DNA (Matthews et al., 1993). We observed that bharangin inhibited the DNA binding of recombinant p65^{+/+}. However, a p65 mutant (C38S) was resistant to this inhibition, suggesting that bharangin can modify Cys³⁸. There are two possibilities by which bharangin can modify p65 at Cys³⁸: 1) by redox cycling, and 2) by direct interaction. Redox cycling results in the generation of reactive oxygen species (ROS) and depletes cellular glutathione level. A previous study demonstrated that the depletion of cellular GSH by diethyl maleate prevented NF-κB induction in rat hepatocytes (Vos et al., 1999). Although our unpublished observations indicated bharangin's potential to generate ROS in cells, its effect is unlikely to be mediated through ROS generation as p65-DNA binding was inhibited in vitro. This eliminates the first possibility. We found that bharangin has potential to dock in to the NF-κB p65. The docking produced a positive total score value of 4.31 indicating strong interaction of the ligand with the protein. Furthermore, the docked structure showed that the bharangin docked in a groove on the receptor surface adjacent to Cys³⁸. The diterpenoid was found to sit in the groove by forming two hydrogen bonds one with Lys³⁷ (2.204 Å) and another with Cys³⁸ (2.023 Å) (Figure 8). Although these observations suggest bharangin's potential to modify p65 at Cys³⁸ by direct interaction, involvement of indirect intermediates cannot be completely ruled out. Our observations thus indicate that bharangin can inhibit NF-κB activation pathway by inhibiting IKK activation and modifying NF-κB p65. Because IKK activation precedes p65 nuclear translocation, we speculate that inhibition of IKK activation by bharangin is a primary step while p65 modification is a secondary step.

MOL #73122

In addition, we found that treatment with bharangin inhibited constitutive NF- κ B activation in myeloma cells. Researchers have reported that constitutive NF- κ B is essential for the proliferation of a number of tumor cells (Bharti et al., 2003; Jackson-Bernitsas et al., 2007; Shishodia et al., 2005). It is not fully understood why tumor cells express constitutively active NF- κ B, but IKK has been implicated (Bharti et al., 2003; Shishodia et al., 2005). In our observations, bharangin inhibited constitutive IKK activation, which may have accounted for bharangin's inhibition of constitutive NF- κ B activation and suppression of tumor-cell proliferation. TNF- α activates NF- κ B via sequential recruitment of TNFR1, TRADD, TRAF2, NIK, TAK1/TAB1, and IKK. Bharangin suppressed the activation of NF- κ B induced by overexpression of these intermediates in our study.

Drug resistance manifested by failure to induce apoptosis is one of the major reasons for failure of cancer therapy. We found that bharangin potentiated apoptosis induced by TNF- α and chemotherapeutic agents in tumor cells. Thus, our results provide an opportunity to use this diterpenoid in combination with existing drugs to induce apoptosis in cancer cells. In this study, we investigated how bharangin potentiate apoptosis in detail. We found that this quinonemethide enhanced cleavage of caspase-3, caspase-8, and caspase-9, suggesting that it can potentiate apoptosis via both extrinsic and intrinsic pathways. We also found that bharangin suppressed the expression of cell-survival proteins. Overexpression of these proteins have been associated with survival and development of chemoresistance and radioresistance in numerous tumor types (Hanahan and Weinberg, 2000). Therefore, inhibition of the expression of these gene products may account for potentiation of apoptosis by bharangin. We also found that bharangin up-regulated expression of the pro-apoptotic protein Bax, suggesting another mechanism by which bharangin enhances TNF- α -induced apoptosis.

MOL #73122

Furthermore, we found that treatment with bharangin inhibited cancer-cell proliferation. Down-regulation of expression of gene products involved in cell proliferation (c-Myc, cyclin D1, and COX-2) may account for observed inhibition of cancer-cell proliferation. In agreement with these observations, previous reports showed that diterpenoids such as oridonin (Ikezoe et al., 2005), ponocidin (Hsieh et al., 2005), and eriocalyxin B (Zhang et al. 2010) can suppress proliferation of a wide variety of cancer cells. In addition, we found that this diterpenoid suppressed the expression of MMP-9 and ICAM-1, two major mediators of tumor-cell invasion (Sun et al., 1999; Watanabe et al., 1993). The down-regulation of expression of these proteins was concomitant with suppression of tumor-cell invasion, suggesting that bharangin has a role in prevention of tumor cell invasion and metastasis. Also, VEGF is a major signaling mediator involved in tumor angiogenesis (Berse et al., 1992). Bharangin's potential to inhibit constitutive and TNF- α -induced VEGF expression suggests that this diterpenoid is an anti-angiogenic agent, as well. The genes involved in tumor cell survival, proliferation, invasion, and angiogenesis are all regulated by NF- κ B (Aggarwal, 2004). The observed inhibition of NF- κ B activation may have accounted for down-regulation of the expression of these gene products by bharangin. In fact, we found that bharangin was unable to potentiate TNF- α -induced apoptosis in p65^{-/-} cells. That the MEF p65^{-/-} cells harboring C38S mutation were insensitive to the bharangin suggest the importance of Cys³⁸ in determining sensitivity against bharangin. We found that bharangin also inhibited proliferation of cancer cells (KBM-5, U-937, HL-60, Jurkat, K-562) that does not express constitutive NF- κ B. Therefore, it is likely that bharangin is modulating pathways other than NF- κ B to suppress tumor cell proliferation.

MOL #73122

Overall, our results indicate that this diterpenoid exhibits anti-cancer potential through inhibition of NF- κ B activation pathway. However, further studies in various animal models are required before its clinical potential is fully realized in cancer prevention and/or treatment.

MOL #73122

Acknowledgments

We thank Don Norwood from Department of Scientific publications for carefully proofreading the manuscript and Dr. Bryant Darnay for supplying the His-MKK6 protein.

MOL #73122

Authorship Contributions

Participated in research design: S.C.G. and B.B.A.

Conducted experiments: S.C.G., R.K., G.M.R. and J.D.

Contributed new reagents or analytical reagents: S.F.K., R.R. and M.S.N.

Performed data analysis: S.C.G., K.J.H. and B.B.A.

Wrote or contributed to the writing of the manuscript: S.C.G. and B.B.A.

MOL #73122

References

- Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. *Nat Rev Immunol* **3**(9):745-756.
- Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. *Cancer Cell* **6**(3):203-208.
- Berse B, Brown LF, Van de Water L, Dvorak HF and Senger DR (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. *Mol Biol Cell* **3**(2):211-220.
- Bharti AC, Donato N, Singh S and Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. *Blood* **101**(3):1053-1062.
- Boonyaratanakornkit L and Chantapavan V (1993) Identification and specification of Khao-Yen-Neua and Khao-Yen-Tai. *Thai J Pharm Sci* **1**:79-90.
- Chen YQ, Ghosh S and Ghosh G (1998) A novel DNA recognition mode by the NF-kappa B p65 homodimer. *Nat Struct Biol* **5**(1):67-73.
- Darnay BG, Ni J, Moore PA and Aggarwal BB (1999) Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. *J Biol Chem* **274**(12):7724-7731.
- Dhamija I, Pai K, Setty M and Manjula S (2008) Evaluation of in vitro and in vivo antitumour activity of alcoholic and ethyl acetate extracts of *Premna herbacea* roxb against tumor models in mice. *Indian J Pharmacol* **40**(Supplement 2):S80-S81.

MOL #73122

- Ghosh G, van Duyne G, Ghosh S and Sigler PB (1995) Structure of NF-kappa B p50 homodimer bound to a kappa B site. *Nature* **373**(6512):303-310.
- Gupta SC, Kim JH, Prasad S and Aggarwal BB (2010a) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. *Cancer Metastasis Rev* **29**(3):405-434.
- Gupta SC, Prasad S, Reuter S, Kannappan R, Yadav VR, Ravindran J, Hema PS, Chaturvedi MM, Nair M and Aggarwal BB (2010c) Modification of c ysteine 179 of I{kappa}B{alpha} kinase by nimbolide leads to down-regulation of NF-{kappa}B-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents. *J Biol Chem* **285**(46):35406-35417.
- Gupta SC, Reuter S, Phromnoi K, Park B, Hema PS, Nair M and Aggarwal BB (2011) Nimbolide sensitizes human colon cancer cells to TRAIL through ROS- and ERK-dependent up-regulation of death receptors, p53, and Bax. *J Biol Chem* **286**(2):1134-1146.
- Gupta SC, Sundaram C, Reuter S and Aggarwal BB (2010b) Inhibiting NF-kappaB activation by small molecules as a therapeutic strategy. *Biochim Biophys Acta* **1799**(10-12):775-787.
- Hanahan D and Weinberg RA (2000) The hallmarks of cancer. *Cell* **100**(1):57-70.
- Hsieh TC, Wijeratne EK, Liang JY, Gunatilaka AL and Wu JM (2005) Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponocidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. *Biochem Biophys Res Commun* **337**(1):224-231.

MOL #73122

- Ikezoe T, Yang Y, Bandobashi K, Saito T, Takemoto S, Machida H, Togitani K, Koeffler HP and Taguchi H (2005) Oridonin, a diterpenoid purified from *Rabdosia rubescens*, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. *Mol Cancer Ther* **4**(4):578-586.
- Itharat A, Singchangchai P and Ratanasuwan P (1998) Wisdom of Southern Thai traditional doctors. *Research Report of Prince of Songkla University, Songkla*:pp. 126.
- Jackson-Bernitsas DG, Ichikawa H, Takada Y, Myers JN, Lin XL, Darnay BG, Chaturvedi MM and Aggarwal BB (2007) Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. *Oncogene* **26**(10):1385-1397.
- Kirtikar K and Basu B (1918) Indian Medicinal Plants. *Lalit Mohan Basu, Allahabad, India* **3**:883-884.
- Kumar R, Pai K, Dhamija I, Setty M, Manjula S and Ramalingayya G (2008) An appraisal of the antitumor activity of alcoholic extract of *Premna herbacea* roxb in Ehrlich's ascetic carcinoma model. *Indian J Pharmacol* **40**(Supplement 2):S67.
- Lakshmi VV, Sridhar P and Polasa H (1989) Loss of plasmid linked antibiotic resistance in *Escherichia coli* on treatment with some phenolic compounds. *FEMS Microbiol Lett* **48**(3):275-278.
- Matthews JR, Kaszubska W, Turcatti G, Wells TN and Hay RT (1993) Role of cysteine62 in DNA recognition by the P50 subunit of NF-kappa B. *Nucleic Acids Res* **21**(8):1727-1734.
- Muller CW, Rey FA, Sodeoka M, Verdine GL and Harrison SC (1995) Structure of the NF-kappa B p50 homodimer bound to DNA. *Nature* **373**(6512):311-317.

MOL #73122

- Murthy MM, Subramanyam M, Giridhar KV and Jetty A (2006) Antimicrobial activities of bharangin from *Premna herbaceae* Roxb. and bharangin monoacetate. *J Ethnopharmacol* **104**(1-2):290-292.
- Narayanan N, Thirugnanasambantham P, Viswanathan S, Kannappa Reddy M, Vijayasekaran V and Sukumar E (2000) Antipyretic, antinociceptive and anti-inflammatory activity of *Premna herbacea* roots. *Fitoterapia* **71**(2):147-153.
- Nayar R, Yoganarsimhan S and Subramanyam K (1976) Pharmacognosy of a local market sample of bharangin: *Pygmacopremna herbaceae*. *Indian J Pharm* **38**:39-44.
- Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. *Nature* **401**(6748):82-85.
- Pai K, Dhamija I, Setty M and Manjula S (2008) Antitumor activity of ethyl acetate extracts of *Premna herbacea* roxb in ehrlich.s ascitic carcinoma Model. *Indian J Pharmacol* **40**(Supplement 2):S67-S68.
- Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB and Aggarwal BB (2007) Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. *J Biol Chem* **282**(24):17340-17350.
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE (2004) UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* **25**(13):1605-1612.

MOL #73122

- Sankaram A, Marthanda Murthi M, Bhaskaraiah K, Narsimha Rao G, Subramanyam M and Shoolery J (1988) Bharangin, a novel diterpenoid quinonemethide from *Pygmacopremna herbaceae*(Roxb.) Moldenke. *Tetrahedron Letters* **29**:245–248.
- Sankaram A and Rao G (1978) Bharangin, a novel diterpenoid quinonemethide from *Pygmacopremna herbaceae*. In: *Proceedings of IUPAC 11th International Symposium of Chemistry of Natural Products* **Vol. 2**:pp. 97–100.
- Sathish T, Brahmaiah P, Sathya K, Bhojaraju P, Naik NG, Kezia D and Prakasam RS (2009) A novel RP-HPLC method for the determination of bharangin in Ghantu bharangi crude extracts. *Pak J Pharm Sci* **22**(1):68-73.
- Shishodia S, Amin HM, Lai R and Aggarwal BB (2005) Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. *Biochem Pharmacol* **70**(5):700-713.
- Sun JJ, Zhou XD, Liu YK, Tang ZY, Feng JX, Zhou G, Xue Q and Chen J (1999) Invasion and metastasis of liver cancer: expression of intercellular adhesion molecule 1. *J Cancer Res Clin Oncol* **125**(1):28-34.
- Takada Y, Khuri FR and Aggarwal BB (2004) Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF -kappaB-regulated gene expression and up-regulation of apoptosis. *J Biol Chem* **279**(25):26287-26299.
- Viatour P, Merville MP, Bours V and Chariot A (2005) Phosphorylation of NF -kappaB and IkappaB proteins: implications in cancer and inflammation. *Trends in biochemical sciences* **30**(1):43-52.

MOL #73122

- Vos TA, Van Goor H, Tuyt L, De Jager-Krieken A, Leuvenink R, Kuipers F, Jansen PL and Moshage H (1999) Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is dependent on the cellular glutathione status. *Hepatology* **29**(2):421-426.
- Watanabe H, Nakanishi I, Yamashita K, Hayakawa T and Okada Y (1993) Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: correlation with cellular invasion. *J Cell Sci* **104** (Pt 4):991-999.
- Zhang YW, Jiang XX, Chen QS, Shi WY, Wang L, Sun HD, Shen ZX, Chen Z, Chen SJ and Zhao WL (2010) Eriocalyxin B induces apoptosis in lymphoma cells through multiple cellular signaling pathways. *Exp Hematol* **38**(3):191-201.

MOL #73122

Footnotes: This research was supported by a grant from the National Institutes of Health through MD Anderson's Cancer Center Support Grant [CA016672], a program project grant from the National Institutes of Health [CA-124787-01A2], and a grant from the MD Anderson Cancer Center for Targeted Therapy. B.B.A. is the Ransom Horne, Jr., Professor of Cancer Research.

MOL #73122

Legends for Figures

Figure 1. Bharangin down-regulates constitutive and inducible NF- κ B activation in cancer cells. (A) The chemical structure of bharangin. (B) Dose- and (C) time-dependent effects of bharangin on TNF- α -induced NF- κ B activation. KBM-5 cells were incubated with (B) bharangin at the indicated concentrations for 6 hours or (C) 5 μ M bharangin for the indicated times and then treated with 0.1 nM TNF- α for 30 minutes. Nuclear extracts of the cells were prepared and assayed for NF- κ B activation using EMSA. The fold activation of NF- κ B and percentage of viable cells (CV) are shown at the bottom. (D) TNF- α -induced NF- κ B is composed of p65 and p50 subunits. Nuclear extracts of untreated cells or cells treated with 0.1 nM TNF- α were incubated with the indicated antibodies, pre-immune serum, an unlabeled NF- κ B oligoprobe, or a mutant oligoprobe and then assayed for NF- κ B activation using EMSA. (E) Bharangin inhibits NF- κ B activation induced by CSC, OA, PMA, and LPS. KBM-5 cells were incubated with 2 and 5 μ M bharangin for 6 hours and then treated with 10 μ g/mL CSC for 1 hour, 500 nM OA for 4 hours, 100 ng/mL PMA for 2 hours, or 10 μ g/mL LPS for 30 minutes. Nuclear extracts of the cells were analyzed for NF- κ B activation using EMSA. The fold activation of NF- κ B as compared with that of control is shown at the bottom. (F) Bharangin suppresses TNF- α -induced NF- κ B activation in different cancer cells. U937, HL-60, Jurkat, and K-562 cells were incubated with 2 and 5 μ M bharangin for 6 hours and then treated with 0.1 nM TNF- α for 30 minutes. Nuclear extracts of the cells were assayed for NF- κ B activation using EMSA. (G) Bharangin suppresses constitutive NF- κ B activation in U266 cells. Cells were incubated with bharangin at the indicated concentrations for 6 hours, and nuclear extracts of the cells were analyzed for NF- κ B activation using EMSA. (H, *left*) Bharangin has no effect on

MOL #73122

TNF- α -induced AP-1 activation. KBM-5 cells were incubated with different concentrations of bharangin for 6 hours, treated with 0.1 nM TNF for 30 minutes and then analyzed for AP-1 activation by EMSA. (H, *right*) Bharangin does not affect the binding of AP-1 to DNA. Nuclear extracts prepared from cells treated with 0.1 nM TNF- α were incubated for 30 minutes with the indicated concentrations of bharangin *in vitro*. The effect of bharangin on AP-1-DNA binding was then analyzed by EMSA. (I) Bharangin does not affect Oct-1 activity. KBM-5 cells were treated with indicated concentrations of bharangin for 6 hours, nuclear extract was prepared and analyzed by EMSA. Results of one of three independent experiments are shown. BG, bharangin; CSC, cigarette smoke condensate; OA, okadaic acid; LPS, lipopolysaccharide; PMA, phorbol myristate acetate.

Figure 2. Bharangin suppresses TNF- α -induced NF- κ B activation via inhibition of IKK activation. (A) KBM-5 cells were preincubated with 5 μ M bharangin for 6 hours and treated with 0.1 nM TNF- α for the indicated times. Nuclear extracts of the cells were analyzed for NF- κ B activation using EMSA. The fold activation of NF- κ B is indicated at the bottom. (B) Western blot analysis of cytoplasmic extracts of KBM-5 cells for I κ B α . (C) Bharangin inhibits TNF- α induced I κ B α phosphorylation. KBM-5 cells were treated with 5 μ M bharangin for 6 hours, incubated with 50 μ g/mL ALLN for 30 minutes, and treated with 0.1 nM TNF- α for 10 minutes. Cytoplasmic extracts of the cells were analyzed using Western blotting with a phosphorylated I κ B α antibody (Ser³²/Ser³⁶). The same membrane was reprobed with I κ B α . (D) Bharangin inhibits TNF- α -induced IKK activation. KBM-5 cells were pretreated with 5 μ M bharangin for 6 hours and then treated with 1 nM TNF- α for the indicated times. Whole-cell extracts of the cells were immunoprecipitated with an antibody against IKK- α and analyzed using an immune

MOL #73122

complex kinase assay. The effect of treatment with bharangin on IKK protein expression was determined using Western blot analysis with anti-IKK- α and anti-IKK- β antibodies. (E) Effect of bharangin on constitutive IKK activation in U266 cells. Cells were treated with 5 μ M bharangin for the indicated times, and whole-cell extracts of the cells were used in an IKK assay. (F) Direct effect of treatment with bharangin on TNF- α -induced IKK activation. Whole-cell extracts of KBM-5 cells treated with 1 nM TNF- α were immunoprecipitated with an IKK- α antibody. The immunoprecipitated complex was incubated with bharangin at the indicated concentrations, and an immunocomplex kinase assay was performed. (G) Effect of bharangin on TNF- α -induced TAK1 activation. KBM-5 cells were preincubated with bharangin (5 μ M) for 6 hours and then treated with TNF- α (1 nM) for the indicated times. The protein extracts were immunoprecipitated with an antibody against TAK1 and analyzed by an immune complex kinase assay. (H) Bharangin does not directly affect TAK1 activity. The protein extract prepared from TNF- α treated KBM-5 cells were immunoprecipitated with an anti-TAK1 and the immunocomplex kinase assay was performed in the absence or presence of the indicated concentrations of bharangin. (I) Effect of bharangin on TNF- α -induced AKT activation. KBM-5 cells were incubated with 5 μ M bharangin for 6 hours and then treated with 1 nM TNF- α for the indicated times. Whole-cell extracts of the cells were prepared and analyzed using Western blotting with a phospho-specific AKT antibody. AKT was used as an internal control. (J) Bharangin inhibits constitutive activation of PI3K, PDK1, mTOR and AKT in U266 cells. Cells were treated with bharangin (5 μ M) for the indicated time. The whole-cell extracts of control and treated cells were analyzed by Western blotting using antibodies against pPI3K, pPDK1, pmTOR, and pAKT. The unphosphorylated protein was used as an internal control. BG, bharangin; GST, glutathione *S*-transferase; His, histidine.

MOL #73122

Figure 3. Bharangin inhibits TNF- α -induced phosphorylation, and nuclear translocation of

p65. (A) Top: KBM-5 cells were treated with 5 μ M bharangin for 6 hours, exposed to 1 nM TNF- α for 15 minutes, and analyzed for p65 localization. Bottom: bharangin induced redistribution of p65 in U266 cells. The cells were incubated with 5 μ M bharangin for 6 hours and analyzed for p65 localization. (B) KBM-5 cells were left untreated or pretreated with 5 μ M bharangin for 6 hours and then treated with 0.1 nM TNF- α for the indicated times. Nuclear extracts of the cells were analyzed using Western blotting with antibodies against p65 and phosphorylated p65 (Ser⁵³⁶ and Ser²⁷⁶). PARP was used as an internal control. The data are from one of three independent experiments. (C) Bharangin inhibits TNF- α -induced MSK1 phosphorylation. KBM-5 cells were first treated with bharangin for 6 hours and then with TNF- α for the indicated time. The nuclear extract prepared from treated and untreated cells was analyzed by western blotting using indicated antibodies. BG, bharangin.

Figure 4. Bharangin inhibits NF- κ B-dependent reporter gene expression induced by TNF-

α and different molecules in the NF- κ B signaling pathway and inhibits direct binding of

p65 to DNA. (A) Bharangin inhibits TNF- α -induced NF- κ B-dependent SEAP expression.

A293 cells were transiently transfected with a plasmid containing a NF- κ B-SEAP gene. Cells were then treated with bharangin at the indicated concentrations for 6 hours followed by 1 nM TNF- α for 24 hours. Cell supernatants were collected and assayed for SEAP activity. The results are expressed as the change in activity relative to that of the vector control. DN, dominant-negative. (B) Bharangin inhibits NF- κ B-dependent reporter gene expression induced by TNF- α , TNFR1, TRADD, TRAF2, NIK, TAK1/TAB1, IKK- β , and p65. A293 cells were transfected

MOL #73122

with a pNF- κ B–SEAP plasmid, expression plasmid, and control plasmid for 24 hours and then treated with bharangin. Cell supernatants were then assayed for SEAP activity. Where indicated, the cells were exposed to 1 nM TNF- α for 12 hours. The results are expressed as the change in activity relative to that of the vector control. The values are the means \pm the SDs for three independent replicates. *, and #- indicates the significance of difference compared to control and TNF- α /plasmid alone group respectively; $P < 0.05$. (C) Bharangin inhibition of direct binding of NF- κ B to DNA. Nuclear extracts of KBM-5 cells from untreated or cells treated with 0.1 nM TNF- α for 30 minutes were incubated with bharangin at the indicated concentrations for 30 minutes and then assayed for NF- κ B activation using EMSA. (D) DTT reverses direct binding of NF- κ B to DNA. Nuclear extracts of TNF- α -treated KBM-5 cells were incubated with 5 μ M bharangin for 30 minutes in the absence or presence of 100 μ M DTT and then assayed for NF- κ B activation using EMSA. (E) DTT reverses bharangin-induced suppression of DNA binding of recombinant p65 in vitro. A293 cells were transfected with a p65 plasmid, and nuclear extracts of the cells were prepared and incubated with 5 μ M bharangin in the absence or presence of DTT for 30 minutes and assayed for NF- κ B activation using EMSA. (F) Lack of an effect of bharangin on DNA binding of mutated p65 (p65-C38S). A293 cells were transfected with p65 wild-type and mutated p65 plasmids. Nuclear extracts of transfected cells were incubated with 5 μ M bharangin for 30 minutes and then assayed for NF- κ B activation using EMSA. BG, bharangin.

Figure 5. Bharangin inhibits TNF- α -induced and constitutive expression of NF- κ B-

dependent anti-apoptotic, proliferative, and metastatic proteins. KBM-5 cells were

incubated with 2 μ M bharangin for 6 hours and then treated with 1 nM TNF- α for the indicated

MOL #73122

times. Also, U266 cells were treated with bharangin at the indicated concentrations for 24 hours. Whole-cell extracts of control and treated cells were analyzed using Western blotting with antibodies against (A) anti-apoptotic, (B) Pro-apoptotic, (C) proliferative, and (D) metastatic and angiogenic proteins. The data are from one of three independent experiments. BG, bharangin.

Figure 6. Bharangin suppresses proliferation and potentiates the TNF- α -induced apoptosis in tumor cells. (A) The indicated cells (3000/100 μ L) were seeded in quadruplicate treated with bharangin at the indicated concentrations, and analyzed for mitochondrial dehydrogenase activity by measuring the absorbance at 570 nm on days 0, 1, 3, and 5. The values are the means \pm the SDs for the four replicates. (B) KBM-5 and U266 cells were pretreated with bharangin at the indicated concentrations for 6 hours and then incubated with 1 nM TNF- α for 24 hours. The cells were stained with a live/dead assay reagent for 30 minutes and analyzed under a fluorescence microscope. Magnification, $\times 100$. Values across each photomicrograph represent mean \pm SD of apoptotic cells (C) Bharangin potentiate TNF- α -induced early apoptosis in KBM-5 cells. Cells were pretreated with 2 μ M bharangin for 6 hours and then incubated with 1 nM TNF- α for 24 hours. Apoptosis was then assessed using a fluorescein isothiocyanate-conjugated annexin V antibody with flow cytometry. (D) Treatment of cells with bharangin before TNF- α induces PARP cleavage. KBM-5 cells were pretreated with 2 μ M bharangin for 6 hours and then incubated with 1 nM TNF- α for the indicated times. Whole-cell extracts were prepared and analyzed using Western blotting with a PARP antibody. (E) Bharangin potentiates TNF- α -induced caspase activation. KBM-5 cells were incubated with 2 μ M bharangin for 6 hours and then treated with 1 nM TNF- α for 24 hours. Whole-cell extracts were prepared and analyzed using Western blotting with the indicated antibodies. (F) Bharangin suppresses TNF- α -induced

MOL #73122

cell invasion. H1299 cells (2.5×10^4) were seeded into the top chamber of a Matrigel invasion chamber system overnight in the absence of serum and then treated with 2 μ M bharangin for 6 hours. Cells were then treated with TNF- α in the presence of 1% serum and assayed for invasion as described in the Methods section. The value for control was set to 1.0. The values are the means \pm the SDs of three replicates. *, # indicate significance of the difference compared with the control and the TNF- α group, respectively; $P < .05$. BG, bharangin.


Figure 7. Deletion of p65 abolishes potentiation of TNF- α -induced apoptosis by bharangin, suppression of TNF- α -induced anti-apoptotic proteins by bharangin requires functional p65 and p65 (C38S) mutants are resistant to bharangin. (A) The p65^{+/+} and p65^{-/-} cells were pretreated with 2 μ M bharangin for 6 hours and then incubated with 1 nM TNF- α for 24 hours. Apoptosis in the cells was assessed using a live/dead assay. Magnification, $\times 100$. Values across each photomicrograph represent mean \pm SD of apoptotic cells (B) The p65^{+/+} and p65^{-/-} cells were pretreated with 2 μ M bharangin for 6 hours and then incubated with 1 nM TNF- α for the indicated times. Whole-cell extracts of cells were prepared and analyzed using Western blotting with the indicated antibodies. (C) The p65^{-/-} cells were transfected with p65 (C38S) plasmid before treatment with bharangin and TNF- α . The apoptosis was examined using live/dead assay (*left*) and anti-apoptotic proteins were examined by western blotting (*right*). The data are from one of three independent experiments. BG, bharangin; MEF, mouse embryonic fibroblast.

Figure 8. Putative bharangin binding site in NF- κ B p65. (*Left*), the surface diagram of p65 (chainA, magenta and chainB, yellow) docked with bharangin (red). (*Right*), expanded view of the region in chainB where bharangin is docked. The groove adjacent to Cys³⁸ (corn flower blue) is the possible binding site of the ligand.


Table 1. Effect of bharangin on apoptosis induced by TNF- α and chemotherapeutic agents in tumor cells


Cell viability (%)													
Cell lines	Medium		TNF- α			5-FU				Thalidomide			
BG (μ M)	2	0	0.5	1	2	0	0.5	1	2	0	0.5	1	2
KBM-5	96 \pm 2.5	95 \pm 5.4	88 \pm 6.6	64 \pm 3.3*	49 \pm 3.4*	96 \pm 3.9	91 \pm 3.7	71 \pm 5.2*	53 \pm 5.5*	94 \pm 7.0	87 \pm 3.4	70 \pm 3.6*	49 \pm 4.7*
Jurkat	94 \pm 4.3	95 \pm 3.5	90 \pm 3.1	63 \pm 4.1*	40 \pm 5.7*	97 \pm 3.1	90 \pm 3.4	74 \pm 4.1*	49 \pm 2.2*	96 \pm 2.9	88 \pm 3.3	76 \pm 4.3*	47 \pm 3.5*
U-937	93 \pm 8.5	94 \pm 2.9	84 \pm 2.7*	66 \pm 2.2*	43 \pm 2.8*	95 \pm 2.5	89 \pm 4.6	72 \pm 4.1*	54 \pm 2.8*	92 \pm 4.9	83 \pm 3.5*	64 \pm 5.9*	42 \pm 2.9*
K-562	92 \pm 5.5	95 \pm 2.4	91 \pm 3.2	56 \pm 2.5*	43 \pm 3.5*	94 \pm 6.2	87 \pm 3.2*	59 \pm 5.4*	49 \pm 3.4*	96 \pm 3.0	80 \pm 3.9*	63 \pm 2.9*	50 \pm 4.1*
U-266	95 \pm 4.0	97 \pm 3.2	86 \pm 4.4*	63 \pm 2.9*	47 \pm 3.6*	95 \pm 1.9	88 \pm 3.0	74 \pm 4.7*	59 \pm 2.7*	94 \pm 5.1	89 \pm 5.1	79 \pm 5.8*	56 \pm 3.9*
MM.1S	94 \pm 6.7	94 \pm 4.7	89 \pm 6.8	74 \pm 5.6*	53 \pm 3.0*	94 \pm 3.1	86 \pm 5.9*	79 \pm 3.3*	54 \pm 3.2*	94 \pm 4.8	87 \pm 5.4*	74 \pm 3.0*	51 \pm 3.3*
RPMI-8226	92 \pm 4.8	94 \pm 4.9	85 \pm 7.0*	67 \pm 2.0*	44 \pm 5.8*	95 \pm 2.1	83 \pm 3.6*	69 \pm 3.0*	51 \pm 5.5*	96 \pm 3.3	87 \pm 5.1*	74 \pm 3.0*	52 \pm 3.3*
HL-60	91 \pm 7.3	96 \pm 2.3	87 \pm 2.3*	73 \pm 2.1*	50 \pm 2.8*	95 \pm 2.3	88 \pm 2.8	74 \pm 2.5*	47 \pm 2.6*	94 \pm 4.6	84 \pm 2.9*	72 \pm 3.3*	46 \pm 2.9*

Cells were pretreated with the indicated concentrations of bharangin, and then incubated with chemotherapeutic agents (1 nM TNF- α , 0.1 μ M 5-FU, and 10 μ g/mL thalidomide) for 24 hours. Cell viability was analyzed by measuring mitochondrial dehydrogenase activity. Values given are mean \pm SD of four replicates. * indicates the significance of difference compared to control; *, $P < 0.05$. BG, bharangin; 5-FU, 5-fluorouracil.



Bharangin (BG)





A

